Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to Alemtuzumab-mediated cytotoxicity

American Journal of Transplantation

Volumn 13, Issue 8, 2013, Pages 2169-2178

  Dons, E M ^a,b   Raimondi, G ^a   Zhang, H ^a   Zahorchak, A F ^a   Bhama, J K ^a   Lu, L ^a   Ezzelarab, M ^a   Ijzermans, J N M ^b   Cooper, D K C ^a   Thomson, A W ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Campath 1H; nonhuman primate; regulatory T cells; transplantation

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; MEMBRANE COFACTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL KILLING; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BINDING; GRAFT RECIPIENT; HEART TRANSPLANTATION; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ALEMTUZUMAB; CAMPATH-1H; NONHUMAN PRIMATE; REGULATORY T CELLS; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ERYTHROCYTES; GLYCOPROTEINS; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; T-LYMPHOCYTES, REGULATORY;

EID: 84881371102     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12248     Document Type: Article

References (25)

1. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H., The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118-127.
2. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-1399.
3. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-515.
4. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128: 260-270.
5. Lowenstein H, Shah A, Chant A, Khan A., Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. Transpl Int 2006; 19: 927-936.
6. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404-406.
7. Wood KJ, Sakaguchi S., Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
8. Bluestone JA., Regulatory T-cell therapy: Is it ready for the clinic ? Nat Rev Immunol 2005; 5: 343-349.
9. Walsh PT, Taylor DK, Turka LA., Tregs and transplantation tolerance. J Clin Invest 2004; 114: 1398-1403.
10. Jiang S, Lechler RI., Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant 2003; 3: 516-524.
11. Wood KJ, Bushell A, Hester J., Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417-430.
12. Raimondi G, Sumpter TL, Matta BM, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010; 184: 624-636.
13. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8: 793-802.
14. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008; 8: 1529-1536.
15. Macedo C, Walters JT, Orkis EA, et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation 2012; 93: 813-821.
16. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
17. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N., A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844-2853.
18. van der Windt DJ, Smetanka C, Macedo C, et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant 2010; 10: 773-783.
19. Perry AC, Jones R, Hall L., Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor. Biochim Biophys Acta 1992; 1171: 122-124.
20. Yeung CH, Schroter S, Wagenfeld A, et al. Interaction of the human epididymal protein CD52 (HE5) with epididymal spermatozoa from men and cynomolgus monkeys. Mol Reprod Dev 1997; 48: 267-275.
21. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-1711.
22. Dons EM, Raimondi G, Cooper DK, Thomson AW., Induced regulatory T cells: Mechanisms of conversion and suppressive potential. Hum Immunol 2012; 73: 328-334.
23. Levitsky J, Leventhal JR, Miller J, et al. Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol 2012; 73: 141-149.
24. Zou L, Barnett B, Safah H, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-8455.
25. Lim CK, Sun L, Feng Q, et al. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. J Hematol Oncol 2008; 1: 19.